Abstract
Background: Endometriosis staging according to the revised American Society for Reproductive Medicine (rASRM) criteria relies on invasive laparoscopic surgery. The development of a reliable, non-invasive method to assess disease severity remains a critical unmet clinical need. Serum cytokines, as mediators of systemic inflammation, represent promising candidate biomarkers for this purpose.
Objective: To identify and validate a panel of serum cytokines capable of distinguishing between different rASRM stages of endometriosis and differentiating patients from disease-free controls.
Methods: In this prospective cross-sectional study, we enrolled 180 participants: 120 women with surgically and histologically confirmed endometriosis (stratified into Stage I-II, n=60; Stage III-IV, n=60) and 60 healthy, age-matched controls. A multiplex bead-based immunoassay was used to quantify 40 cytokines in serum samples. Machine learning algorithms, primarily Random Forest, were employed for feature selection and the development of a discriminatory biomarker panel.
Results: Univariate analysis identified eight cytokines with significant differential expression across groups: IL-8, TNF-α, VEGF-A, IL-1β, MCP-1, IL-10, IL-17A, and IFN-γ. A combined panel of IL-8, VEGF-A, and TNF-α demonstrated superior discriminatory power. This panel differentiated controls from all endometriosis patients with an area under the curve (AUC) of 0.94 (95% CI: 0.90–0.98). Most notably, it distinguished early-stage (I-II) from advanced-stage (III-IV) disease with an AUC of 0.87 (95% CI: 0.81–0.93). Serum levels of VEGF-A and IL-8 showed strong positive correlations with total rASRM scores.
Conclusion: We have identified a novel three-cytokine serum signature (IL-8, VEGF-A, TNF-α) with high diagnostic accuracy for both the detection and surgical staging of endometriosis. This "liquid biopsy" approach holds significant potential to revolutionize patient management by enabling non-invasive triage, personalizing therapeutic strategies, and reducing diagnostic delay.
Keywords
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.